Active, not recruitingPhase 3NCT04759586
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Studying Primary mediastinal large B-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Lisa G RothChildren's Oncology Group
- Intervention
- Biospecimen Collection(procedure)
- Enrollment
- 244 target
- Eligibility
- 2 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Children's Hospital of Alabama, Birmingham, Alabama, United States
- USA Health Strada Patient Care Center, Mobile, Alabama, United States
- Providence Alaska Medical Center, Anchorage, Alaska, United States
- Banner Children's at Desert, Mesa, Arizona, United States
- Banner University Medical Center - Tucson, Tucson, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- UC Irvine Health Cancer Center-Newport, Costa Mesa, California, United States
- Kaiser Permanente Downey Medical Center, Downey, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
- City of Hope at Irvine Lennar, Irvine, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Cedars Sinai Medical Center, Los Angeles, California, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04759586 on ClinicalTrials.govOther trials for Primary mediastinal large B-cell lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONPHASE1NCT07168486CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasUniversity of Maryland, Baltimore
- RECRUITINGPHASE2NCT06500273Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLAllogene Therapeutics
- ACTIVE NOT RECRUITINGPHASE1NCT05757700Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell LymphomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT05653271ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell MalignanciesAcepodia Biotech, Inc.
- ACTIVE NOT RECRUITINGNCT06024694Primary Mediastinal Large B-cell Lymphoma With CNS InvolvementIRCCS San Raffaele
- RECRUITINGNCT05366569Bio-CAR-T BS StudyAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
- RECRUITINGPHASE2NCT04745949PACIFIC: Primary Mediastinal Large B-cell Lymphoma Treated With Antibody Therapy, Checkpoint Inhibitor in Frontline With ImmunoChemotherapyM.D. Anderson Cancer Center
- RECRUITINGNANCT04824950Circulating Tumor DNA in Primary Mediastinal Large B-cell Lymphoma (PMBL)Centre Henri Becquerel
See all trials for Primary mediastinal large B-cell lymphoma →